We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


Designs and provides products for clinical laboratory and blood screening, including testing items for detection of h... read more Featured Products: More products

Download Mobile App

Hologic to Sell Blood-Screening Business to Grifols for USD 1.85 Billion

By LabMedica International staff writers
Posted on 15 Dec 2016
Print article
US medical device maker Hologic, Inc. (Bedford, MA, USA) has agreed to sell off its share of the Procleix blood-screening business to long-time partner, Grifols SA (Barcelona, Spain), for USD 1.85 billion in cash.

Hologic develops, manufactures, and supplies diagnostic products, medical imaging systems, and surgical products. The company's core business units focus on diagnostics, breast health, gynecological surgery, and skeletal health. Since 1998, Hologic has worked with Grifol, which develops plasma protein therapies, to develop their blood-screening business.

The Procleix blood-screening business offers molecular assays and instruments to blood banks for screening donated blood, prior to transfusion, for viruses including HIV, hepatitis C and B, West Nile and Zika. Hologic handles research and development and manufacturing of the Procleix blood-screening products, while Grifols is responsible for selling the molecular assays and instruments.

As per the deal, which has been approved by boards of both the companies, Grifols will acquire Hologic's blood-screening manufacturing facility in Rancho Bernardo, California, as well as the development rights, licenses to patents and access to product manufacturers. Hologic will retain the engineering expertise associated with the blood-screening systems including Tigris and Panther, but will continue to work with Grifols to ensure that its customers have access to its blood-screening instruments over the long-term.

"Divesting our share of our blood screening business to Grifols will strengthen our efforts to build a sustainable growth company by accelerating top- and bottom-line growth rates, while significantly increasing financial flexibility," said Hologic’s chairman, president and CEO, Steve MacMillan. "We are immensely proud of the contributions we have made to global blood safety over nearly 20 years. But at the same time, we believe that the business and our blood screening employees are best positioned to succeed under a single owner, and that this sale to Grifols provides excellent value for Hologic and our shareholders."

Related Links:
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Plasma Control
Plasma Control Level 1

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more


view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.